Aspect Biosystems: $115 Million (Series B) Secured To Develop Bioprinted Tissue Therapeutics
By Amit Chowdhry ● Jan 10, 2025
Aspect Biosystems - a biotechnology company advancing the development of bioprinted tissue therapeutics as a new category in regenerative medicine - announced that it has closed a $115 million Series B funding round. This funding round was led by Dimension, a multistage investment firm dedicated to the interface of technology and the life sciences, with participation from existing and new investors, including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.